In addition to providing insights into the impact of BTK inhibition (BTKi) on responses of B cells and B-cell:T-cell interactions of potential relevance to the therapeutic mechanism of action of BTKi in MS, our study reveals a novel mechanism involving metabolic regulation of B-cell effector functions. Here, IBTK is linked to myeloid sarcoma.